Loading patent…
AssigneePliant Therapeutics, Inc.
InventorsEric LEFEBVRE, Johanna Roberta SCHAUB
Estimating the term…
The disclosure relates to methods of (i) treating a subject for a liver fibrotic disease, in particular, primary sclerosing cholangitis or (ii) modulating αVβ6 integrin, αVβ1 integrin, or both αVβ6 integrin and αVβ1 integrin in a subject in need thereof, comprising administration of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4- ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein. Optionally, a second drug, such as ursodeoxycholic acid or a pharmaceutically acceptable salt thereof, can be co-administered. The compounds and pharmaceutical compositions thereof are αVβ6 integrin inhibitors that are useful for treating fibrosis such as primary sclerosing cholangitis.
A method of ameliorating pruritus in a human who has fibrotic liver disease comprising administering to the human(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof.
A method of ameliorating fibrosis in a tissue of a human in need thereof, comprising administering to the human(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof, wherein the tissue is liver tissue, gall bladder tissue, or bile duct tissue.
5-10. (canceled)
The method of, wherein the human has primary sclerosing cholangitis.
A method of treating primary sclerosing cholangitis in a human in need thereof, comprising administering to the human(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof, wherein primary sclerosing cholangitis in the human is ameliorated.
13-17. (canceled)
20-38. (canceled)
40-45. (canceled)
(canceled)
49-52. (canceled)
54-63. (canceled)
65-77. (canceled)
79-85. (canceled)
87-89. (canceled)
91-94. (canceled)
96-98. (canceled)
100-101. (canceled)
103-108. (canceled)
110-132. (canceled)
Dependencies are inferred from the claim text.